← Back to patent-cliff list
比克恩丙诺
Tier B — Position earlyBictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate
Gilead Inc
Originator
2018
First approval
-
Expiry (public)
$14.33B ▲
Peak sales
化学药
Type
Targets：HIV-1 RT、HIV integrase、RT
Brand：Biktarvy、必妥维
Indications (approved)：HIV感染
Regional status
US
批准上市
2018-02-07
EU
批准上市
2018-06-21
China
批准上市
2019-08-02
Japan
批准上市
2019-03-26
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate?
Approved indications include: HIV感染.
When does the Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate patent expire?
No public expiry year is available for Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate yet; this page updates once verified.
How do I get a quote for Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24